News

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

Non-dilutive capital finances planned launch of ensifentrine…

ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia

Inglewood, California, October 17th 2022 – ImaginAb, Inc.,…

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona…

Muna Therapeutics Awarded $4.9M Grant from The Michael J. Fox Foundation for Parkinson’s Research Supports Development of Disease Modifying Therapy for Parkinson’s Disease

Copenhagen, Denmark and Boston, US, 11th October 2022 – Muna…

Novo Nordisk Foundation establishes fellowships with four top international universities

The Novo Nordisk Foundation is expanding and extending its Interdisciplinary…

Novo Nordisk Foundation and World Food Programme launch partnership to improve food systems in Rwanda and Uganda

Copenhagen – The Novo Nordisk Foundation and the United Nations…

Panaxia and Neuraxpharm to enter new medical cannabis markets in Europe

Both companies will expand their cooperation through the distribution…

Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors

Financing led by Brandon Capital, Forbion and Atlas Venture …

Destiny Pharma plc – Notice of R&D Update Meeting

Brighton, United Kingdom – 22 September 2022 – Destiny…

Novo Nordisk Foundation: Major investment for developing Denmark’s first fully functional quantum computer

Denmark’s first fully functional generally applicable quantum…

World-class translational project enters the Bio Studio program as part of collaboration with Imperial College London

BioInnovation Institute (BII) announces that it has entered a…

Ariceum Therapeutics Q4 2022 Investor and Scientific Conference

BERLIN, 15 September 2022 – Ariceum Therapeutics (Ariceum),…

Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022

AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix…

Futura Medical Interim Results for the Six Months ended 30 June 2022

Futura Medical plc (AIM: FUM), a pharmaceutical company developing…

Fierce Biotech names STORM Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

STORM recognised as an innovative early-stage biotechnology company…

Sequana Medical announces H1 2022 results and provides business update

alfapump® – strong interim data / on track to report primary…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.